Premium
Reduced vascular basement‐membrane immunostaining in mucinous tumours of the ovary
Author(s) -
Orre Maxine,
Rogers Peter A. W.
Publication year - 1998
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19980417)79:2<139::aid-ijc7>3.0.co;2-u
Subject(s) - pathology , immunostaining , cd31 , angiogenesis , serous fluid , basement membrane , clear cell , immunohistochemistry , biology , ovary , blood vessel , microvessel , medicine , cancer research , endocrinology
Tumour vasculature is heterogeneous, exhibiting a range of vessel densities and the vascular basement membrane (VBM) of tumour blood vessels may be fragmented or absent. Increased microvessel density (MVD) has been reported in mucinous ovarian tumours as compared with other histologic sub‐types. We hypothesized that VBM immunostaining differs between regions of the ovarian tumour vasculature and between ovarian tumour types exhibiting different MVD. Serial sections from 56 ovarian tumours were immunostained using antibodies to the VBM components collagen IV, heparan sulphate proteoglycan and laminin, and the endothelial cell marker CD31. Regions of high and average MVD were selected, and the number of vessels positive for each VBM component were counted and expressed as a percentage of the number of CD31‐positive vessels. The percentage of VBM‐positive vessels did not differ between the high and average MVD regions of borderline or malignant, mucinous and serous tumours. The percentage of VBM‐positive vessels in mucinous tumours was less than that observed in malignant and borderline serous tumours and benign tumours ( p < 0.02). Possible explanations for these findings are (i) that VBM turnover is similar throughout the vasculature; (ii) that the VBM is present both during angiogenesis and in the newly formed vessels of high MVD regions; or (iii) that an alternative angiogenesis mechanism is utilized in different ovarian tumour types, or even between different regions of the same tumour. Int. J. Cancer (Pred. Oncol.) 79:139–143, 1998.© 1998 Wiley‐Liss, Inc.